Projects per year
Personal profile
Education
- 2006-2012 Ph.D., Department of Pharmacy, National Taiwan University
- 2005-2006 M.S., Department of Pharmacy, National Taiwan University
- 2000-2005 B.S., Department of Pharmacy, National Taiwan University
Experience
- 2020.08- Associate Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
- 2016.03-2020.07 Assistant Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
- 2016.01-2016.03 Postdoctoral Research Fellow, Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
- 2013.07-2014.02 Postdoctoral Research Scholar, Academia Sinica
- 2012.02-2013.06 Postdoctoral Research Fellow, National Taiwan University
Awards
- 2019 Young Researcher Award, Taipei Medical University
Research Interests
- 藥理及毒理
- 藥學
Fingerprint
Dive into the research topics where Chun-Han Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
天然物對兒童高惡性度神經膠質細胞瘤之治療潛力及其分子作用機轉探討(2/3)
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
天然物對兒童高惡性度神經膠質細胞瘤之治療潛力及其分子作用機轉探討(1/3)
8/1/21 → 7/31/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
研究CK1delta與CK1epsilon在腎臟細胞癌進展的角色，並評估其專一性抑制劑在治療上的可行性與藥理機轉探討
3/1/21 → 2/28/22
Project: C - Project of Alliance › o - Chi Mei Medical Center
-
利用轉錄體學與蛋白質體學方法探討膀胱癌對鉑類藥物產生抗藥性之分子機轉研究並開發新的治療策略(第二年)
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
-
Using Transcriptomic and Proteomic Approaches to Investigate the Molecular Mechanisms of Platinum-Resistance in Bladder Cancer and Develop New Therapeutic Strategies
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
-
Combining an autophagy inhibitor, mpt0l145, with abemaciclib is a new therapeutic strategy in gbm treatment
Hsieh, T. H., Liang, M. L., Zheng, J. H., Lin, Y. C., Yang, Y. C. S. H., Vo, T. H., Liou, J. P., Yen, Y. & Chen, C. H., Dec 1 2021, In: Cancers. 13, 23, 6117.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
Differential co-occurring patterns between depressive symptomatology and sleep-wake-related disturbances in mood disorders
Chen, S. Y., Chen, C. H., Lo, C., Lu, M. L., Hsu, C. D., Chiu, Y. H., Chen, C. H., Lin, S. K., Huang, M. C., Chen, H. C. & Kuo, P. H., 2021, In: Nature and Science of Sleep. 13, p. 503-514 12 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus) -
Abemaciclib, a selective cdk4/6 inhibitor, restricts the growth of pediatric ependymomas
Liang, M. L., Chen, C-H., Liu, Y-R., Huang, M. H., Lin, Y. C., Wong, T. T., Lin, S. E., Chu, S. S., Ding, Y. H. & Hsieh, T-H., Dec 2020, In: Cancers. 12, 12, p. 1-17 17 p., 3597.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus) -
CK1δ as a potential therapeutic target to treat bladder cancer
Lin, Y. C., Chen, M. C., Hsieh, T. H., Liou, J. P. & Chen, C. H., Apr 15 2020, In: Aging. 12, 7, p. 5764-5780 17 p.Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus) -
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Jun 15 2020, In: European Journal of Medicinal Chemistry. 196, 112329.Research output: Contribution to journal › Comment/debate › peer-review
Open Access